Organization (Academic)
Wuhan University
ClinicalTrials.gov lists Wuhan University as lead sponsor of 46 trials. It has 15 active development programs and 11 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 1 registered with a 2026 start date. The dashed outline is the pace from the 1 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 4.6 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers Wuhan University: 46 lead-sponsored trials and 1 legal-entity registration.
Disease areas (92)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Lung Neoplasms | 10 |
| Colorectal Neoplasms | 8 |
| Head and Neck Neoplasms | 8 |
| Carcinoma, Non-Small-Cell Lung | 7 |
| Stomach Neoplasms | 7 |
Showing 5 of 92 disease areas.
Trials by start year as sponsor or collaborator (19)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 1 |
| 2025 | 7 |
| 2024 | 4 |
| 2023 | 4 |
| 2022 | 7 |
| 2021 | 5 |
| 2020 | 14 |
| 2019 | 7 |
| 2018 | 11 |
| 2017 | 2 |
Showing 10 of 19 years.
Prediction, not a registry value: median 36 months or more (the model's horizon) from start to primary completion across 7 trials still running at the 2026-10-09 snapshot; 5 of 7 predicted trials reach the 36-month horizon; registered median of 26 months across 11 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (15)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| Sintilimab | Esophageal Neoplasms | Phase 2 | 1 |
| Sintilimab | Head and Neck Neoplasms | Phase 2 | 1 |
| Sintilimab | Esophageal Squamous Cell Carcinoma | Phase 2 | 1 |
| Sintilimab | Carcinoma, Squamous Cell | Phase 2 | 1 |
| CARBOPLATIN | Carcinoma, Non-Small-Cell Lung | Phase 2 | 1 |
Showing 5 of 15 active programs.
Approved assets (11)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| Digaoxin,amiodarone,β receptor antagonist, Calcium Antagonists | 1 |
| Pyrotinib Maleate Tablets | 1 |
| CYCLOPHOSPHAMIDE | 3 |
| Vincristine | 3 |
| DOXORUBICIN | 3 |
Showing 5 of 11 approved assets.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 30% hit target (n=10) | 56% on time (n=9) |
Journals published in (139)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| The New England journal of medicine | 8 |
| Anesthesiology | 5 |
| Clinical cancer research : an official journal of the American Association for Cancer Research | 5 |
| Journal of the American College of Cardiology | 5 |
| Lancet (London, England) | 5 |
Showing 5 of 139 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 150 | 114 | 2025-12-23 |
Organization relationships (121)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Tongji Hospital | Co sponsors trial with | 10 |
| Wuhan Union Hospital | Co sponsors trial with | 9 |
| Cancer Hospital of Guizhou Province | Co sponsors trial with | 5 |
| Xiangya Hospital Central South University | Co sponsors trial with | 5 |
| Renji Hospital | Co sponsors trial with | 4 |
Showing 5 of 121 relationships.
Latest dated events (246)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-02-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-12-23 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2025-12-02 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2025-12-02 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2025-11-25 | Patent granted | Granted US patents (PatentsView / USPTO) |
Showing 5 of 246 events.
Biomarker capability evidence (57)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| ALB | Trial collaborator | Named in trial inclusion criteria |
| ALB | Trial sponsor | Named in trial inclusion criteria |
| ALB | Trial collaborator | Named in trial inclusion criteria |
| ALB | Trial collaborator | Named in trial inclusion criteria |
| ALK | Trial sponsor | Named in trial inclusion criteria |
Showing 5 of 57 evidence rows.
Biomarkers this organization publishes on (303)
Shown in this order: most publications first.
Showing 5 of 303 biomarkers.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, and clia clinical laboratory certificates.